Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Cancer's "undead" cells may be more manageable than we thought. A new study reveals that cellular senescence unfolds in stages — not all at once — and that it's possible to block the harmful inflammatory signals these dormant tumor cells release without waking them back up. The findings could pave the way for safer, more effective cancer combination therapies.
Cancer's "undead" cells may be more manageable than we thought. Many cancer therapies don't kill tumor cells outright — instead, they push them into cellular senescence, a state where cells stop dividing but remain alive and active. These dormant cells release a mix of signaling molecules (called SASP) that can both help the immune system and fuel chronic inflammation that encourages tumor growth. Until now, scientists weren't sure what triggered that harmful inflammatory response — or whether it could be stopped without letting cancer cells start dividing again.
A new study published in Life Science Alliance answers both questions. Researchers compared two cancer treatments — the chemotherapy doxorubicin (which damages DNA) and the CDK4/6 inhibitor palbociclib (which halts cell division without DNA damage) — and found that despite taking very different paths, both ultimately activate the same inflammatory program driven by NF-κB. Crucially, the team showed it's possible to block NF-κB and suppress the inflammatory response without reversing the cells' growth arrest.
Key Takeaways:
Why it matters: This research opens the door to combination therapies that preserve the tumor-suppressing benefits of senescence while neutralizing its pro-inflammatory risks — potentially extending survival for patients with cancers like liposarcoma and ER-positive breast cancer.
